Panbela Therapeutics (PBLA) Competitors $0.16 +0.00 (+1.91%) As of 07/3/2025 12:09 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. SNOA, GLTO, LIPO, MTNB, MBIO, RDHL, SNGX, INM, CNSP, and TTNPShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Sonoma Pharmaceuticals (SNOA), Galecto (GLTO), Lipella Pharmaceuticals (LIPO), Matinas Biopharma (MTNB), Mustang Bio (MBIO), Redhill Biopharma (RDHL), Soligenix (SNGX), InMed Pharmaceuticals (INM), CNS Pharmaceuticals (CNSP), and Titan Pharmaceuticals (TTNP). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors Sonoma Pharmaceuticals Galecto Lipella Pharmaceuticals Matinas Biopharma Mustang Bio Redhill Biopharma Soligenix InMed Pharmaceuticals CNS Pharmaceuticals Titan Pharmaceuticals Panbela Therapeutics (NASDAQ:PBLA) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation. Does the media favor PBLA or SNOA? In the previous week, Panbela Therapeutics' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score. Company Overall Sentiment Panbela Therapeutics Neutral Sonoma Pharmaceuticals Neutral Do insiders and institutionals believe in PBLA or SNOA? 4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate PBLA or SNOA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PBLA or SNOA more profitable? Panbela Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -24.23%. Panbela Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Panbela TherapeuticsN/A N/A -302.61% Sonoma Pharmaceuticals -24.23%-58.73%-21.05% Which has more risk & volatility, PBLA or SNOA? Panbela Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Which has preferable valuation and earnings, PBLA or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Panbela Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPanbela TherapeuticsN/AN/A-$25.26M-$71.130.00Sonoma Pharmaceuticals$14.29M0.34-$3.46M-$3.10-0.96 SummaryPanbela Therapeutics beats Sonoma Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$777K$839.46M$5.56B$9.04BDividend YieldN/A4.84%5.24%4.01%P/E Ratio0.001.1527.6120.24Price / SalesN/A228.55417.30118.22Price / CashN/A23.4436.8958.10Price / Book-0.016.328.035.67Net Income-$25.26M-$27.99M$3.18B$249.21M7 Day Performance-23.81%2.11%2.93%3.28%1 Month Performance-43.68%10.13%3.75%5.55%1 Year Performance-56.40%11.60%35.20%21.09% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.082 of 5 stars$0.16+1.9%N/A-55.8%$777KN/A0.006SNOASonoma PharmaceuticalsN/A$2.93-0.3%N/A+969.6%$4.81M$14.29M-0.95180Positive NewsGLTOGalecto3.395 of 5 stars$3.50+3.9%$10.00+185.7%-72.8%$4.63MN/A-0.2340Gap DownLIPOLipella Pharmaceuticals1.3314 of 5 stars$1.02-7.3%N/A-77.9%$4.56M$540K-0.254MTNBMatinas BiopharmaN/A$0.90+1.7%N/AN/A$4.55M$1.10M-0.1830MBIOMustang Bio1.0202 of 5 stars$1.04+0.5%N/A-95.0%$4.53MN/A-0.01100RDHLRedhill BiopharmaN/A$1.92+1.3%N/A-99.1%$4.39M$8.04M0.00210SNGXSoligenix1.505 of 5 stars$1.36-17.6%N/A-46.9%$4.39M$120K-0.3120News CoveragePositive NewsHigh Trading VolumeINMInMed Pharmaceuticals1.0974 of 5 stars$3.58+45.9%N/A-42.8%$4.29M$4.92M-0.2910Analyst UpgradeGap DownHigh Trading VolumeCNSPCNS Pharmaceuticals1.6873 of 5 stars$0.76+0.1%$25.00+3,189.5%-98.7%$4.15MN/A0.005News CoverageTTNPTitan Pharmaceuticals0.3004 of 5 stars$4.52+6.1%N/A-17.1%$4.11M$180K-0.9810Gap Down Related Companies and Tools Related Companies Sonoma Pharmaceuticals Competitors Galecto Competitors Lipella Pharmaceuticals Competitors Matinas Biopharma Competitors Mustang Bio Competitors Redhill Biopharma Competitors Soligenix Competitors InMed Pharmaceuticals Competitors CNS Pharmaceuticals Competitors Titan Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
